Sigma Healthcare has recorded strong sales and profit growth in its financial results for the half year ending 31 December 2025.
Highlights included a normalised EBIT of $582.9 million, up 18.7% on the previous corresponding period, and revenue of $5.5 billion, up 14.9%.
Sales for Australian Chemist Warehouse stores came in at $5.1 billion, up 17.2%, while international stores recorded a 24.5% increase in sales to $807 million.
“The first half performance underscores the strength of our integrated business model and the compelling opportunities ahead,” said CEO and managing director Vikesh Ramsunder.
“We are delivering growth across all markets and channels, strengthening our product capability and progressing the integration with discipline.
“With solid trading momentum and synergy benefits still ahead of us, Sigma is well positioned to deliver sustained growth and long-term shareholder value,” Ramsunder concluded.
More details in today’s issue of Pharmacy Daily.
